Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 268479, 7 pages
http://dx.doi.org/10.1155/2014/268479
Review Article

The Role of PAM4 in the Management of Pancreatic Cancer: Diagnosis, Radioimmunodetection, and Radioimmunotherapy

Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University Medical Center, Xi’an, Shannxi 710061, China

Received 16 January 2014; Accepted 18 March 2014; Published 10 April 2014

Academic Editor: Aurelia Rughetti

Copyright © 2014 Suxia Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. V. Gold, G. Newsome, D. Liu, and D. M. Goldenberg, “Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin,” Molecular Cancer, vol. 12, no. 11, p. 143, 2013. View at Publisher · View at Google Scholar
  2. D. V. Gold, K. Lew, R. Maliniak, M. Hernandez, and T. Cardillo, “Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin,” International Journal of Cancer, vol. 57, no. 2, pp. 204–210, 1994. View at Google Scholar · View at Scopus
  3. D. V. Gold, Z. Karanjawala, D. E. Modrak, D. M. Goldenberg, and R. H. Hruban, “PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma,” Clinical Cancer Research, vol. 13, no. 24, pp. 7380–7387, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Raimondi, P. Maisonneuve, and A. B. Lowenfels, “Epidemiology of pancreatic cancer: an overview,” Nature Reviews Gastroenterology and Hepatology, vol. 6, no. 12, pp. 699–708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA: A Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Google Scholar
  6. D. Yadav and A. B. Lowenfels, “The epidemiology of pancreatitis and pancreatic cancer,” Gastroenterology, vol. 144, no. 6, pp. 1252–1261, 2013. View at Google Scholar
  7. M. Hidalgo, “Pancreatic cancer,” The New England Journal of Medicine, vol. 363, no. 3, p. 298, 2010. View at Google Scholar
  8. S. P. Raman, K. M. Horton, and E. K. Fishman, “Multimodality imaging of pancreatic cancer—computed tomography, magnetic resonance imaging, and positron emission tomography,” The Cancer Journal, vol. 18, no. 6, pp. 511–522, 2012. View at Google Scholar
  9. J. Gaa, A. A. Fingerle, K. Holzapfel, and E. J. Rummeny, “MRI for malignant pancreatic tumors,” Radiologe, vol. 49, no. 2, pp. 124–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. W. Saif, “Controversies in the adjuvant treatment of pancreatic adenocarcinoma,” Journal of the Pancreas, vol. 8, no. 5, pp. 545–552, 2007. View at Google Scholar · View at Scopus
  11. P. Michl and T. M. Gress, “Current concepts and novel targets in advanced pancreatic cancer,” Gut, vol. 62, no. 2, pp. 317–326, 2013. View at Google Scholar
  12. X. Xu, L. Bai, W. Chen et al., “MUC1 contributes to BPDE-induced human bronchial epithelial cell transformation through facilitating EGFR activation,” PLoS ONE, vol. 7, no. 3, Article ID e33846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Cascio, A. M. Farkas, R. P. Hughey, and O. J. Finn, “Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration,” Oncotarget, vol. 4, no. 10, pp. 1686–1697, 2013. View at Google Scholar
  14. Q. Chen, D. Li, J. Ren et al., “MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress,” Biochemical and Biophysical Research Communications, vol. 440, no. 1, pp. 179–183, 2013. View at Publisher · View at Google Scholar
  15. B. Agrawal, S. J. Gendler, and B. M. Longenecker, “The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy,” Molecular Medicine Today, vol. 4, no. 9, pp. 397–403, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Nath, K. Daneshvar, L. D. Roy et al., “MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes,” Oncogenesis, vol. 2, p. e51, 2013. View at Google Scholar
  17. G. Mariani, N. Molea, D. Bacciardi et al., “Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer,” Cancer Research, vol. 55, supplement 23, pp. 5911s–5915s, 1995. View at Google Scholar · View at Scopus
  18. A. Gnoni, A. Licchetta, A. Scarpa et al., “Carcinogenesis of pancreatic adenocarcinoma: precursor lesions,” International Journal of Molecular Sciences, vol. 14, no. 10, pp. 19731–19762, 2013. View at Google Scholar
  19. G. Zamboni, K. Hirabayashi, P. Castelli et al., “Precancerous lesions of the pancreas,” Best Practice & Research Clinical Gastroenterology, vol. 27, no. 2, pp. 299–322, 2013. View at Google Scholar
  20. D. V. Gold, M. Goggins, D. E. Modrak et al., “Detection of early-stage pancreatic adenocarcinoma,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 11, pp. 2786–2794, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. D. V. Gold, D. E. Modrak, Z. Ying, T. M. Cardillo, R. M. Sharkey, and D. M. Goldenberg, “New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis,” Journal of Clinical Oncology, vol. 24, no. 2, pp. 252–258, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. D. V. Gold, J. Gaedcke, B. M. Ghadimi et al., “PAM4 enzyme immunoassay alone and in combination with ca19-9 for the detection of pancreatic adenocarcinoma,” Cancer, vol. 119, no. 3, pp. 522–528, 2013. View at Google Scholar
  23. D. V. Gold, R. Alisauskas, and R. M. Sharkey, “Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4,” Cancer Research, vol. 55, no. 5, pp. 1105–1110, 1995. View at Google Scholar · View at Scopus
  24. D. V. Gold, T. Cardillo, D. M. Goldenberg, and R. M. Sharkey, “Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4,” Critical Reviews in Oncology/Hematology, vol. 39, no. 1-2, pp. 147–154, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Alisauskus, G. Y. C. Wong, and D. V. Gold, “Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer,” Cancer Research, vol. 55, supplement 23, pp. 5743s–5748s, 1995. View at Google Scholar · View at Scopus
  26. T. M. Cardillo, Z. Ying, and D. V. Gold, “Therapeutic advantage of 90yttrium- versus 131iodine-labeled PAM4 antibody in experimental pancreatic cancer,” Clinical Cancer Research, vol. 7, no. 10, pp. 3186–3192, 2001. View at Google Scholar · View at Scopus
  27. S. A. Gulec, S. J. Cohen, K. L. Pennington et al., “Treatment of advanced pancreatic carcinoma with 90Y-clivatuzumab tetraxetan: a phase I single-dose escalation trial,” Clinical Cancer Research, vol. 17, no. 12, pp. 4091–4100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Chopra, “111In/125/131I-labeled anti-mucin-1 murine, chimeric or humanized antibody hPAM4,” Molecular Imaging & Contrast Agent Database, 2011. View at Google Scholar
  29. A. J. Ocean, K. L. Pennington, M. J. Guarino et al., “Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial,” Cancer, vol. 118, no. 22, pp. 5497–5506, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. T. M. Cardillo, H. Karacay, D. M. Goldenberg et al., “Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy,” Clinical Cancer Research, vol. 10, no. 10, pp. 3552–3561, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Chopra, “125I-labeled anti-mucin 1 bispecific antibody bsPAM4,” Molecular Imaging & Contrast Agent Database, 2011. View at Google Scholar
  32. A. Chopra, “99 mTc-Ac-Lys(DTPA)-Tyr-Lys(DTPA)-Lys (thiosemicarbazonyl-glyoxyl-cysteinyl-)-NH2 (IMP-192) [[99 mTc]-IMP-192],” Molecular Imaging & Contrast Agent Database, 2011. View at Google Scholar
  33. A. Chopra, “111In-labeled Ac-Phe-Lys(DTPA)-Tyr-Lys(DTPA)-NH2 (IMP-156) [[111In]-IMP-156],” Molecular Imaging & Contrast Agent Database, 2011. View at Google Scholar
  34. D. V. Gold, D. M. Goldenberg, H. Karacay et al., “A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma,” Cancer Research, vol. 68, no. 12, pp. 4819–4826, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Chopra, “111In-labeled 1, 4, 7, 10-tetraazacyclododecane-N, N', N”, N”'-tetraacetic acid (DOTA)-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2 (IMP-288) [[111In]-IMP-288],” Molecular Imaging & Contrast Agent Database, 2011. View at Google Scholar
  36. A. Chopra, “125I-labeled trivalent, bispecific monoclonal antibody construct TF10 that targets mucin-1 and is reactive against a histamine-succinyl-glycine hapten IMP-288 [[125I]-TP10],” Molecular Imaging & Contrast Agent Database, 2011. View at Google Scholar
  37. D. V. Gold, T. Cardillo, Y. Vardi, and R. Blumenthal, “Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4,” International Journal of Cancer, vol. 71, no. 4, pp. 660–667, 1997. View at Google Scholar
  38. D. V. Gold, D. E. Modrak, K. Schutsky, and T. M. Cardillo, “Combined 90Yttrium-Dota-Labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft,” International Journal of Cancer, vol. 109, no. 4, pp. 618–626, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. T. M. Cardillo, R. Blumenthal, Z. Ying, and D. V. Gold, “Combined Gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer,” International Journal of Cancer, vol. 97, no. 3, pp. 386–392, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. D. V. Gold, K. Schutsky, D. Modrak, and T. M. Cardillo, “Low-dose radioimmunotherapy (90Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer,” Clinical Cancer Research, vol. 9, supplement 10, part 2, pp. 3929S–3937S, 2003. View at Google Scholar · View at Scopus
  41. H. Karacay, R. M. Sharkey, D. V. Gold et al., “Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10- 90Y-IMP-288 alone and combined with gemcitabine,” Journal of Nuclear Medicine, vol. 50, no. 12, pp. 2008–2016, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. E. S. Glazer, C. Zhu, K. L. Massey et al., “Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles,” Clinical Cancer Research, vol. 16, no. 23, pp. 5712–5721, 2010. View at Publisher · View at Google Scholar · View at Scopus